$2.30
24.51%
Nasdaq, Oct 23, 03:53 pm EDT. Closed.
ISIN
US98973P1012
Symbol
TCRT

ZIOPHARM Oncology, Inc. Stock price

$3.04
+1.77 139.37% 1M
+0.31 11.36% 6M
-0.19 5.88% YTD
+0.48 18.75% 1Y
-13.48 81.59% 3Y
-233.96 98.72% 5Y
-805.46 99.62% 10Y
-821.96 99.63% 20Y
Nasdaq, Closing price Thu, Oct 22 2026
-0.04 1.30%
ISIN
US98973P1012
Symbol
TCRT
Industry

Is ZIOPHARM Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$8.9m
Enterprise Value
$8.8m
Net debt
positive
Cash
$120.0k
Shares outstanding
2.5m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
13.7
Financial Health
Equity Ratio
72.6%
Return on Equity
-194.0%
ROCE
-614.9%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$930.0k | -
SBC as % of FCF
-
SBC Growth 1Y
126.8%
Share Count Growth 1Y
20.3%
Shareholder Yield
-20.3%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-4.0m
EBIT
$-4.1m
Net Income
$-4.0m
Free Cash Flow | ex SBC
$-2.7m | $-3.7m
Growth
Revenue | estimate
-100.0% | -100.0%
EBITDA
0.2%
EBIT
-0.5%
Net Income
-0.5%
Free Cash Flow
4.2%
Margin
Gross
-
EBITDA
-134,466.7%
EBIT
-135,266.7%
Net
-133,666.7%
Free Cash Flow | ex SBC
-90,900.0% | -121,933.3%
More
EPS
$-1.6
FCF per Share
$-1.1
Short interest
0.4%
Employees
1
Rev per Employee
$10.0k

ZIOPHARM Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

Hold
50%
Sell
50%

Financial data from ZIOPHARM Oncology, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.42 2.42
30% 30%
-
- Research and Development Expense 1.65 1.65
143% 143%
-
-4.03 -4.03
0% 0%
-
- Depreciation and Amortization 0.02 0.02
-
-
EBIT (Operating Income) EBIT -4.06 -4.06
1% 1%
-
Net Profit -4.01 -4.01
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about ZIOPHARM Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ZIOPHARM Oncology, Inc. Stock News

Neutral
GlobeNewsWire
●
10 days ago
Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
Neutral
PRNewsWire
●
10 days ago
Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team BOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs (together with related entities, "Paragon"), a biotechnology compan...
Neutral
GlobeNewsWire
●
about one month ago
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
More ZIOPHARM Oncology, Inc. News

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Head office United States
CEO Mr. Weis
Employees 1
Founded 2003
Website alaunos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today